HM Payson & Co’s Novavax NVAX Stock Holding History

HM Payson & Co’s Portfolio NVAX Stock Details NVAX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q4	–	Sell	-1,273	Closed	-$9.22K	–	1018
2023 Q3	$9.22K	Hold	1,273	–	–	﹤0.01%	831
2023 Q2	$9.46K	Buy	1,273 +65	+5%	+$511	﹤0.01%	810
2023 Q1	$8.37K	Hold	1,208	–	–	﹤0.01%	813
2022 Q4	$12.4K	Hold	1,208	–	–	﹤0.01%	727
2022 Q3	$22K	Hold	1,208	–	–	﹤0.01%	684
2022 Q2	$62K	Hold	1,208	–	–	﹤0.01%	550
2022 Q1	$89K	Hold	1,208	–	–	﹤0.01%	513
2021 Q4	$173K	Buy	1,208 +9	+0.8%	+$1.55K	﹤0.01%	423
2021 Q3	$249K	Sell	1,199 -200	-14%	-$44.1K	0.01%	364
2021 Q2	$297K	Hold	1,399	–	–	0.01%	338
2021 Q1	$254K	Hold	1,399	–	–	0.01%	363
2020 Q4	$156K	Buy	1,399 +4	+0.3%	+$425	﹤0.01%	427
2020 Q3	$151K	Hold	1,395	–	–	﹤0.01%	399
2020 Q2	$116K	Buy	1,395 +195	+16%	+$7.46K	﹤0.01%	419
2020 Q1	$16K	Buy	+1,200	New	+$10.2K	﹤0.01%	682

Other funds holding NVAX

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

SCM

Shah Capital Management Raleigh, North Carolina $521M AUM 46.95% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Rafferty Asset Management New York $24.6B AUM 47.06% 1-Year Est. Return

Coatue Management New York $29.1B AUM 96.54% 1-Year Est. Return

Bank of Montreal Toronto, Ontario, Canada $269B AUM 31.4% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

HM Payson & Co's NVAX Position: Q4 2023 in Review

HM Payson & Co sold out of Novavax (NVAX) in Q4 2023, closing a stake of 1,273 shares — an estimated $9.22K sold.

HM Payson & Co first reported a position in NVAX in Q1 2020 and held it in 15 quarters. The position peaked at $297K in Q2 2021. 199 funds tracked by Wall St. Rank hold NVAX as of Q4 2023.

HM Payson & Co reported no remaining Novavax position as of Q4 2023 after selling out during the quarter.
HM Payson & Co sold 1,273 Novavax shares in Q4 2023, an estimated $9.22K.
HM Payson & Co first reported a position in Novavax in Q1 2020 and held it in 15 quarters.
HM Payson & Co's Novavax position peaked at $297K in Q2 2021.
199 funds tracked by Wall St. Rank held Novavax as of Q4 2023.

Based on HM Payson & Co's 13F filing for Q4 2023, filed 13 Feb 2024.